EP3918095A1 - Piscine orthoreovirus virulence markers - Google Patents

Piscine orthoreovirus virulence markers

Info

Publication number
EP3918095A1
EP3918095A1 EP20704957.8A EP20704957A EP3918095A1 EP 3918095 A1 EP3918095 A1 EP 3918095A1 EP 20704957 A EP20704957 A EP 20704957A EP 3918095 A1 EP3918095 A1 EP 3918095A1
Authority
EP
European Patent Office
Prior art keywords
seq
virus
confirms
mortality
snp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20704957.8A
Other languages
German (de)
French (fr)
Inventor
Magnus Andreas DEVOLD
Morten Lund
Håvard AANES
Linda Ramsevik Teigene
Vidar Teis ASPEHAUG
Gordon RICHIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patogen As
Original Assignee
Patogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patogen As filed Critical Patogen As
Publication of EP3918095A1 publication Critical patent/EP3918095A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12241—Use of virus, viral particle or viral elements as a vector
    • C12N2720/12243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus

Definitions

  • SEQ ID NO. 30 confirms the virus to have SNP S4-G754A
  • SEQ ID NO. 46 confirms the virus to have SNP M2-A1108G
  • the invention further relates to a method as described above, wherein the absence of all SNPs mentioned in table 1 above, confirms the virus to be nonvirulent, and not cause mortality or morbidity.
  • a method according to the above may be carried out, comprising use of a primer and probe comprising a sequence of at least 10 consecutive nucleotides according to the following
  • primers acc. to SEQ ID NO. 40 and 41 and probe acc. to SEQ ID NO. 43, confirm the absence of SNP M2-G784T,
  • PRV isolates from 3 freshwater sites and 17 seawater sites where the fish had developed HSMI were selected, the genomic material of the samples were isolated, and the genomic material was sequenced. Further, the amino acid sequences of the sample were isolated and sequenced.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to methods for determining virulence of PRV in a biological sample from a fish, comprising detection of SNPs. The invention further relates to 5primers and probes to be used in such a method.

Description

Piscine Orthoreovirus Virulence Markers
The present invention relates to methods for determining virulence of Piscine orthoreovirus (PRV), and primers and probes to be used in such a method, according to the preamble of the independent patent claims.
Background
The aquaculture industry is an important food source and income, and Salmonids in particular are very popular farmed species in many regions of the world. Viral diseases pose a significant threat to the productivity in aquaculture, and thus impact the future global aquaculture production. Heart and Skeletal Muscle Inflammation (HSMI) has become a serious disease in farmed salmonids in several geographical areas. It was discovered in salmon in the sea in Norway in 1999, and is now reported from fresh and seawater sites in for instance UK, Scotland, Canada and Chile. The causal relationship between the PRV and HSMI was described by (Wessel 0, et al. (2017) Infection with purified Piscine orthoreovirus demonstrates a causal relationship with heart and skeletal muscle inflammation in Atlantic salmon. PLoS ONE 12(8):e0183781). The mortality during HSMI outbreaks varies from negligible to 20 %.
According to The National Veterinary Institute the virus has spread over the years and in 2014 the virus was delisted from notifiable diseases. The delisting was done because the PRV is ubiquitous in Atlantic salmon, and thus present also in healthy individuals not associated with clinical disease. Still, HSMI is a significant health problem for the aquaculture industry in Norway, but it is not yet possible to differentiate between virulent and less virulent or non-virulent strains of PRV.
Reoviruses are non-enveloped icosahedral viruses with double-stranded RNA genomes comprising 10-12 segments and consistent with the genome organization characteristic for members of the family Reoviridae, the genome of the PRV comprises at least 10 RNA segments (GenBank Accession numbers GU994013- GU994022). Palacios et al 2010, identified these 10 different segments as L1 , L2,
L3, M1 , M2, M3, S1 , S2, S3 and S4 (Palacios G, et al. (2010) Heart and Skeletal Muscle Inflammation of Farmed Salmon Is Associated with Infection with a Novel Reovirus. PLoS ONE 5(7): e11487).
Viruses closely related to PRV from farmed Atlantic salmon have been discovered in association with diseases in other salmonid species. A virus called PRV-2 was demonstrated to be the possible causative agent of erythrocytic inclusion body syndrome (EIBS), a disease that can cause mass mortality in Coho salmon
( Oncorhynchus kisutch ). Another PRV-like virus was detected in association with a disease outbreak in rainbow trout ( Oncorhynchus mykiss) in Norway; the fish displayed signs of circulatory disturbance and histopathological changes resembling HSMI. Furthermore, a PRV strain closely related to the PRV from rainbow trout was found in association with HSMI-like lesions in Coho salmon in Chile. The presence of several PRV variants associated with diseases in salmonids suggests that species adaptation is important for pathogenesis (Wessel 2017).
Siah et al 2015 conducted a phylogenetic study of PRV strains from Norway,
Canada and Chile, and found that Norwegian strains differed in S1 segment. Wessel et al have shown the genetic relationship of strains from different regions and species, and shows that strains from Atlantic salmon all belong to the same group. Parts of the genome of the Norwegian strain is sequenced, and known for instance from Genbank. However, also in Norway there are fish detected positive to PRV without clinical symptoms, and fish detected positive to PRV developing HSMI.
Therefore it is important to have diagnostic tools to differentiate between the strains that can cause disease, and those that do not.
The current diagnostic methods are histology, immunohistochemistry, virus propagation, serology, neutralizing assay, sequencing and PCR, wherein PCR gives the fastest result and is the preferred method. EP 2482825 describes a known method for determining the presence or absence of piscine reovirus, by using PCR. The genomes of all organisms undergo spontaneous mutations during their continuing evolution, forming variant forms of progenitor genetic sequences. A mutation may result in an evolutionary advantage or disadvantage relative to a progenitor form or may be neutral. A variant that result in an evolutionary advantage may eventually be incorporated in many members of the species and may thus effectively become the progenitor form. Furthermore, often various variant forms survive and coexist in a species population. The coexistence of multiple forms of a genetic sequence gives rise to genetic polymorphism, including single-nucleotide polymorphisms (SNPs).
A single-nucleotide polymorphism (SNP) is a DNA sequence variation occurring when a single nucleotide— A, T, C or G— in the genome (or other shared sequence such as RNA) differs between members of a biological species or paired chromosomes in an organism. For example, two DNA fragments from different individuals, AAGCCTA to AAGCTTA, contain a difference in a single nucleotide, commonly referred as two alleles. Almost all common SNPs have only two alleles. The genomic distribution of SNPs is not homogenous; SNPs usually occur in non coding regions more frequently than in coding regions or, in general, where natural selection is acting the allele of the SNP that constitutes the most favorable genetic adaptation is predominating.
The invention
The issues set out above are solved by methods, primers and probes according to the characterizing part of the enclosed independent claims. Further advantageous features are stated in the corresponding dependent claims.
The present invention relates to a method for determining virulence of Piscine Orthoreovirus (PRV) in a biological sample from a fish, comprising a step for detecting whether any of the following single nucleotide polymorphisms (SNPs) are present in the genomic material
S4-T320C or S4-G754A in SEQ ID NO. 4, M2-G551C, M2-T580A, M2-G784T, M2-A958G, or M2-A1108G in SEQ ID
NO. 5,
M3-A280T, M3-C371T, M3-C1064T, M3-A1351G, M3-T1421C or M3-T1687C in SEQ ID NO. 6,
or the complementary oligonucleotides thereof, wherein the numbering of said positions are in accordance with sequences 4, 5, and 6, respectively, wherein presence of at least one SNP confirms that the virus is virulent and will cause morbidity and/or mortality of a fish upon infection. The SNPs as mentioned above are to be understood as defined in table 1 below.
The SNP S4-T320C should thus be understood to mean a mutation from T to C in position 320 of the S4 segment. The reference segment of S4 is shown in SEQ ID NO. 4.
Virulence is a measure of the pathogenicity of an organism. The degree of virulence is related directly to the ability of the organism to cause disease despite host resistance mechanisms. In one embodiment, the method further comprises a step for isolating the genomic material from the biological sample, and possibly a step for sequencing the material before detecting the SNPs. The step for detection of the SNPs may be performed in many ways which will be obvious to a skilled person, and the necessity of isolating and sequencing depends on the detection method.
In a preferred embodiment, any sequencing, is performed by a polymerase chain reaction and use of at least one primer. The sequencing may also be performed by Next Generation Sequencing Methods, such as a method selected from the group consisting of lllumina (Solexa) sequencing, Roche 454 sequencing, Ion Torrent and SOLiD sequencing.
The detection of SNPs may be performed by manual or automatic comparing the sequenced genomic material from the sample with the reference.
In a preferred embodiment of the invention, the step of detecting comprises use of a polymerase chain reaction and use of at least one primer and/or probe.
In a preferred embodiment, each primer or probe used for sequencing or detecting comprise a sequence of at least 10 consecutive nucleotides selected from one of the sequences of a group consisting of SEQ ID NO. 24-26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58 and 60-63.
In a preferred embodiment, the primers used for sequencing or detecting are used as primer pairs, selected from a group consisting of the following primer pairs:
primers according to SEQ ID NO. 24 and 25,
primers according to SEQ ID NO. 28 and 29,
primers according to SEQ ID NO. 32 and 33,
primers according to SEQ ID NO. 36 and 37,
primers according to SEQ ID NO. 40 and 41 ,
primers according to SEQ ID NO. 44 and 45,
primers according to SEQ ID NO. 48 and 49,
primers according to SEQ ID NO. 52 and 53,
primers according to SEQ ID NO. 56 and 57, and primers according to SEQ ID NO. 60 and 61.
In a preferred embodiment, the step of detecting comprises use of probes, preferably in a PCR reaction, wherein binding of a probe comprising a sequence of at least 10 consecutive nucleotides from
SEQ ID NO. 26, confirms the virus to have SNP S4-T320C
SEQ ID NO. 30, confirms the virus to have SNP S4-G754A
SEQ ID NO. 34, confirms the virus to have SNP M2-G551C
SEQ ID NO. 38, confirms the virus to have SNP M2-T580A
SEQ ID NO. 42, confirms the virus to have SNP M2-G784T
SEQ ID NO. 46, confirms the virus to have SNP M2-A1108G
SEQ ID NO. 50, confirms the virus to have SNP M3-A280T
SEQ ID NO. 54, confirms the virus to have SNP M3-C371T
SEQ ID NO. 58, confirms the virus to have SNP M3-A1351G
SEQ ID NO. 62 or 63, confirms the virus to have SNP M3-T1687C
The invention further relates to a method as described above, wherein the presence of mutation M3-A280T and/or M3-A1351G in SEQ ID NO. 6 confirms the virus to cause high mortality.
The invention further relates to a method as described above, wherein the presence of mutations M3-A280T, M3-C1064T, M3-A1351G, M3-T1421C and M3-T1687C in SEQ ID NO. 6 confirm the virus to cause high mortality. The invention further relates to a method as described above, wherein the presence of mutations S4-G754A, M2-G551C, M2-T580A, M2-G784T, M2-A958G, M2- A1108G, M3-A280T, M3-C1064T, M3-A1351G, M3-T1421C, and M3-T1687C in SEQ ID NO. 6 confirm the virus to cause high mortality. The invention further relates to a method as described above, wherein the presence of mutation M3-C371T in SEQ ID NO. 6 confirms the virus to cause moderate to low mortality, and morbidity. The invention further relates to a method as described above, wherein the presence of mutations M3-C371T, M3-C1064T and M3-T1421C in SEQ ID NO. 6 confirm the virus to cause moderate to low mortality, and morbidity.
The invention further relates to a method as described above, wherein the presence of mutations S4-G754A, M2-G551C, M2-G784T, M2-A958G, M2-A1108G, M3- C371T, M3-C1064T, and M3-T1421C in SEQ ID NO. 6 confirm the virus to cause moderate to low mortality, and morbidity.
The invention further relates to a method as described above, wherein the presence of mutation S4-T320C in SEQ ID NO. 4 confirms the virus to cause high morbidity.
The invention further relates to a method as described above, wherein the presence of mutations S4-T320C, M2-G551C, M2-T580A, M2-G784T, M2-A958G, M2- A1108G, M3-C1064T, M3-T1421C and M3-T1687C in SEQ ID NO. 6 confirms the virus to cause high morbidity.
The invention further relates to a method as described above, wherein the presence of mutation S4-G754A in SEQ ID NO. 4 confirms the virus to cause high to moderate mortality, and morbidity.
The invention further relates to a method as described above, wherein the absence of all SNPs mentioned in table 1 above, confirms the virus to be nonvirulent, and not cause mortality or morbidity. In order to prove the absence of all SNPs, a method according to the above may be carried out, comprising use of a primer and probe comprising a sequence of at least 10 consecutive nucleotides according to the following
primers acc. to SEQ ID NO. 24 and 25, and probe acc. to SEQ ID NO. 27, confirm the absence of SNP S4-T320C,
primers acc. to SEQ ID NO. 28 and 29, and probe acc. to SEQ ID NO. 31 , confirm the absence of SNP S4-G754A, primers acc. to SEQ ID NO. 32 and 33, and probe acc. to SEQ ID NO. 35, confirm the absence of SNP M2-G551 C,
primers acc. to SEQ ID NO. 36 and 37, and probe acc. to SEQ ID NO. 39, confirm the absence of SNP M2-T580A,
primers acc. to SEQ ID NO. 40 and 41 , and probe acc. to SEQ ID NO. 43, confirm the absence of SNP M2-G784T,
primers acc. to SEQ ID NO. 44 and 45, and probe acc. to SEQ ID NO. 47, confirm the absence of SNP M2-A1108G,
primers acc. to SEQ ID NO. 48 and 49, and probe acc. to SEQ ID NO. 51 , confirm the absence of SNP M3-A280T,
primers acc. to SEQ ID NO. 52 and 53, and probe acc. to SEQ ID NO. 55, confirm the absence of SNP M3-C371T,
primers acc. to SEQ ID NO. 56 and 57, and probe acc. to SEQ ID NO. 59, confirm the absence of SNP M3-A1351 G,
primers acc. to SEQ ID NO. 60 and 61 , and probe acc. to SEQ ID NO. 64, confirm the absence of SNP M3-T1687C
The invention also relates to a primer or probe comprising a sequence of at least 10 consecutive nucleotides selected from the group comprising SEQ ID NO. 24-26, 28- 30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58 and 60-63. The primer or probe may comprise any 10 consecutive nucleotides from SEQ ID NO. 24, or from SEQ ID NO. 25, or from SEQ ID NO. 26 etc. The primer or probe may also comprise, or be identical to, the mentioned sequences.
The invention further relates to a method for determining virulence of Piscine Orthoreovirus (PRV) in a biological sample from a fish, comprising the following steps,
a) isolating amino acid sequences of the sample,
b) sequencing the amino acid sequence,
c) detecting whether any of the following amino acids are present in the amino acid sequences
- A in position 107 or N in position 252 of SEQ ID NO. 1 - T in position 184, I in position 194, S in position 262, A in position 320 or D in position 370 of SEQ ID NO. 2, or
- L in position 94, V in position 124, L in position 355, V in position 451 , T in position 474 or P in position 563 of SEQ ID NO. 3
wherein the numbering of said positions are in accordance with the sequences SEQ ID NO. 1 , 2 and 3, respectively,
wherein presence of at least one of the amino acids confirms that the virus is virulent and will cause morbidity and/or mortality of the fish upon infection.
If none of the following amino acids are present, A in position 107 or N in position 252 of SEQ ID NO. 1 , T in position 184, I in position 194, S in position 262, A in position 320 or D in position 370 of SEQ ID NO. 2, or L in position 94, V in position 124, L in position 355, V in position 451 , T in position 474 or P in position 563 of SEQ ID NO. 3, then the virus is non-virulent.
The invention further relates to a method as described above, wherein the presence of amino acid L in position 94, and/or V in position 451 in SEQ ID NO. 3 confirms the virus to cause high mortality.
The invention further relates to a method as described above, wherein the presence of L in position 94, L in position 355, V in position 451 , T in position 474 and P in position 563 of SEQ ID NO. 3 confirms the virus to cause high mortality.
The invention further relates to a method as described above, wherein the presence of N in position 252 of SEQ ID NO. 1 , T in position 184, I in position 194, S in position 262, A in position 320 and D in position 370 of SEQ ID NO. 2, and L in position 94, L in position 355, V in position 451 , T in position 474 and P in position 563 of SEQ ID NO. 3 confirms the virus to cause high mortality.
The invention further relates to a method as described above, wherein the presence of V in position 124 of SEQ ID NO. 3 confirms the virus to cause moderate mortality, high morbidity. The invention further relates to a method as described above, wherein the presence of V in position 124, L in position 355, and T in position 474 of SEQ ID NO. 3 confirms the virus to cause moderate mortality, high morbidity.
The invention further relates to a method as described above, wherein the presence of - N in position 252 of SEQ ID NO. 1 , and T in position 184, S in position 262, A in position 320 and D in position 370 of SEQ ID NO. 2, and V in position 124, L in position 355, and T in position 474 of SEQ ID NO. 3 confirms the virus to cause moderate mortality, high morbidity.
The invention further relates to a method as described above, wherein the presence of A in position 107 of SEQ ID NO. 1 , and T in position 184, I in position 194, S in position 262, A in position 320 and D in position 370 of SEQ ID NO. 2, and L in position 355, T in position 474 and P in position 563 of SEQ ID NO. 3
confirms the virus to cause high morbidity.
The invention further relates to a method as described above, wherein the presence of N in position 252 of SEQ ID NO. 1 confirms the virus to cause moderate mortality, high morbidity.
Figures
The invention will now be described in detail with reference to the enclosed Figures and sequences where
Fig. 1 shows an alignment of PRV protein S4, from GenBank AGR27923 (SEQ ID NO. 1) and from a virulent virus strain (SEQ ID NO. 7-8), AGR27923 is cut 17 amino acids at the end,
Fig. 2 shows an alignment of PRV Protein M2 (SEQ ID NO. 2), from GenBank AGR27919 and from a virulent virus strain (SEQ ID NO. 9-10),
Fig. 3 shows an alignment of PRV Protein M3 (SEQ ID NO. 3), from GenBank AGR27920 and from a virulent virus strain (SEQ ID NO. 11-13) Fig. 4 shows an alignment of the nucleotide encoding S4, from GenBank KC715687 (SEQ ID NO. 4) and from a virulent virus strain (SEQ ID NO. 14-16) KC715687 is cut 38 nucleotides at 5 end and 105 at 3 end,
Fig. 5 shows an alignment of the nucleotide encoding M2, from GenBank KC715683 (SEQ ID NO. 5) and from a virulent virus strain (SEQ ID NO. 17-20) KC715683 is cut with 26 nucleotides at 5 end and 87 at 3 end,
Fig. 6 shows an alignment of the nucleotide encoding M3, from GenBank KC715684 (SEQ ID NO. 6) and from a virulent virus strain (SEQ ID NO. 21-23) KC715684 is cut with 83 nucleotides at 5 end and 60 at 3 end,
Fig. 7 shows a phylogenetic tree of S4,
Fig. 8. shows accumulated mortality associated with the PRV genotypes of virulent virus, wherein Fig 8.A shows HSMI mortality and Fig 8.B. shows mortality of looser fish also called morbidity. The enclosed nucleotide sequences are
Description of preferred embodiments of the invention
Reference throughout the description to "an embodiment" signifies that a particular feature, structure or property specified in connection with an embodiment is included in the least in one embodiment. The expressions "in one embodiment", "in a preferred embodiment" or "in an alternative embodiment" different places in the description does not necessarily point to the same embodiment. Further, the different features, structures or properties may be combined in any suitable way in one or more of the embodiments.
Example 1 :
This study describes different genotypes of PRV isolates collected from farmed Atlantic salmon in Norway.
Materials and methods
Tissue samples of heart, head or kidney from HSMI diseased farmed Atlantic salmon were collected from aquaculture farms in Norway and tested for PRV by RT-qPCR. The samples were collected from 11 freshwater sites and 29 seawater sites during the years 2014 to 2016. The samples were collected aseptically on tubes prefilled with RNAIater (Ambion, USA). After sampling, the tubes containing tissue samples were shipped chilled to PatoGen AS with 24-hour delivery service.
The RT-qPCR assay targeting PRV were performed, the method is validated according to ISO17025 standards and is described elsewhere (Glover et al. 2013).
Amino acid changes can be detected by different methods, such as protein sequencing, DNA or RNA sequencing, or by Real Time qPCR SNP assay. The two last methods are easier and more cost effective than protein sequencing. In this example DNA/RNA sequencing by Sanger and by Real Time PCR were used.
PRV isolates from 3 freshwater sites and 17 seawater sites where the fish had developed HSMI, were selected, the genomic material of the samples were isolated, and the genomic material was sequenced. Further, the amino acid sequences of the sample were isolated and sequenced.
A retrospective epidemiological study was performed to investigate whether specific PRV genotypes was associated with HSMI mortality and/or morbidity (including looser fish). The data was collected from salmon farms in Norway. Looser fish is fish not developing and acting normal, it is often smaller than normal fish, has a higher mortality rate and it cannot be sent to the marked once slaughtered. In the following, virus causing looser fish will be referred to as virus causing morbidity.
Results
All samples confirmed positive to PRV in standard qPCR testing. The phylogenetic analyses generated 3 distinct groups shown as A, B and C in figure 7, in addition to the reference.
The genomic material and the amino acid sequences of the sample were compared to a Canadian from Genbank named VT06062012-358 (herein called reference or reference virus), defined as non-virulent, where
SEQ ID NO. 1 shows a truncated version of the amino acid sequence of S4, being the outer fiber protein, and
SEQ ID NO. 4 shows a truncated version the nucleotide sequence of the S4 segment, encoding the outer fiber protein,
SEQ ID NO. 2 shows the amino acid sequence of M2 segment being the outer shell protein, and
SEQ ID NO. 5 shows a truncated version of the nucleotide sequence of the M2 segment encoding the outer shell protein, and SEQ ID NO. 3 shows the amino acid sequence of M3 segment, encoding a non- structural factory protein, and
SEQ ID NO. 6 shows a truncated version of the nucleotide sequence of the M3 segment encoding the non-structural factory protein,
of the reference virus.
Sequences for both the proteins and the nucleotide sequences encoding the proteins were aligned with the reference. The alignments are enclosed as Figure 1 and 4, regarding S4 segment, Figure 2 and 5 regarding M2 segment and Figure 3 and 6 regarding M3 segment. Genotype groups were established, named A, B and C. In the alignments both SNPs causing an amino acid change and silent mutations are shown.
Regarding the S4 segment, the genotype groups A and C of the protein are identical. The sequences of A/C and B are enclosed as SEQ ID NO. 7 and 8 respectively. The genotype groups A, B and C of the nucleotide sequence are unique, and enclosed as SEQ ID NO. 14-16.
Regarding the M2 segment, there were 4 genotype groups, A, A-2, B and C, where the proteins of A-2 and B, and A and C are identical, sequences of which are enclosed as SEQ ID NO. 9 and 10, respectively. The groups A, A-2, B and C of the nucleotide sequence are unique, and enclosed as SEQ ID NO. 17-20, respectively.
Regarding the M3 segment, the genotype groups of the proteins were unique, the sequences are enclosed as SEQ ID NO. 11-13, showing genotype group A, B and C respectively. The genotype groups A, B and C of the nucleotide sequence are also unique, and enclosed as SEQ ID NO. 21-23, respectively.
The three different genogroups identified 13 different unique changes in amino acids that are associated to virulence (Table 2). It is the amino acids that are the basis for the genogrouping. There were slight variations in silent mutations in addition, that did not cause any change in amino acid. Table 2. Amino acid differences identified in PRV strains.
In the epidemiological study the accumulated mortality and morbidity (e.g. looser fish) were recorded. The mortality and morbidity observations correlated well with the 3 genogroups A, B and C. The reference was not detected in any of the sites. Six PRV-isolates grouped into genogroup C, 9 PRV-isolates into the genogroup A and 5 PRV-isolates into the genogroup B (Table 3). Although several amino acid changes can be seen in several genogroups, these may also be important to predict the strains' ability to induce mortality and or morbidity, relatively to the non-virulent reference.
Table 3. PRV isolates with data about HSMI mortality grouped into genotypes. FW: freshwater site. SI/I/: seawater site.
The result from the epidemiological study showed that the PRV genotype A was associated to higher level of HSMI mortality. The genogroup B was associated with high morbidity (looser fish) and less mortality. The genogroup C was associated with lower mortality and morbidity (looser fish). Accumulated mortality associated with the PRV genotypes is shown in Figure 8, where fig. 8A shows the HSMI mortality and Fig 8.B. shows % mortality that is of looser fish, also called morbidity. The figure also show the the 25th and 75th percentiles. A correlation between the genogroups and the mortality from the epidemiological data were confirmed. Regarding figure 8B, the lower and upper border of boxes indicates the 25th and 75th percentiles, respectively and the centerline indicates the 50th percentile. The upper and lower whiskers correspond to the highest and lowest value of the 1.5*IQR (inter-quartile range). The differences between genogroups, are reflected in the 13 amino acid changes shown in Table 2.
Example 2:
In order to determine whether a fish is infected by a PRV virus causing mortality and/or morbidity, or a nonvirulent virus, primers and probes proving the presence or absence of the SNPs according to the present invention were developed. If one or more of the SNPs are present, then the virus is virulent and will cause morbidity and/or mortality of a fish upon infection. Based on this, 10 different Real Time SNP assays were designed to detect amino acid changes (Table 4). The probe 1 detect the virulent mutation, and probe 2 detect the reference being nonvirulent.
All SNP’s can also be detected by sequencing, for the virulence markers M2-320, M3-355 and M3-474 only sequencing are used. Table 4 Primer pairs and probes (assays) for detection of the SNPs related to the invention. Probe 1 (P1) detect virulent strains of the virus, P2 detect the reference virus.
Example 3:
Test of assays. To validate that the Real Time PCR SNP assays (Example 2) can differentiate between the different groups, 3 assays was tested on field samples from Example 1. The assays SNP S4-T320C, M3-C371T and M3-A1351G, detecting B, C and A respectively, were used.
The assays give a differentiation in Ct values and the probe giving the lowest Ct values indicates which SNP mutation that is most frequent in the biologic sample. The detected SNPs are marked in Bold in table 5 below.
Table 5: Three assays tested on biological samples, and Ct values from PCR.
*ND = Not Detected. This shows that if the P1 probe has the lowest Ct value, when using the SNP assay S4-T320C, the virus is of genotype B. The same is shown for the SNP assays M3- C371T and M3-A1351G; if P1 has the lowest Ct value, the sample is of genotypes C and A respectively.

Claims

Patent claims
1. Method for determining virulence of Piscine Orthoreovirus (PRV) in a biological sample from a fish, comprising a step for detecting whether any of the following single nucleotide polymorphisms (SNPs) are present in the genomic material
S4-T320C or S4-G754A in SEQ ID NO. 4,
M2-G551C, M2-T580A, M2-G784T, M2-A958G, or M2-A1108G in SEQ ID
NO. 5,
M3-A280T, M3-C371T, M3-C1064T, M3-A1351G, M3-T1421C or M3-T1687C in SEQ ID NO. 6,
or the complementary oligonucleotides thereof, wherein the numbering of said positions are in accordance with sequences SEQ ID NO. 4, 5 or 6, respectively,
wherein presence of at least one SNP confirms that the virus is virulent and will cause morbidity and/or mortality of a fish upon infection.
2. Method according to claim 1 , comprising a step for isolating the genomic material from the sample, before detecting the SNPs.
3. Method according to claim 1 or 2, comprising a further step between isolating and detecting, for sequencing the genomic material.
4. Method according to claim 3, wherein the sequencing is performed by a method selected from the group consisting in lllumina (Solexa) sequencing, Roche 454 sequencing, Ion Torrent and SOLiD sequencing.
5. Method according to claim 3, wherein the sequencing is performed by a polymerase chain reaction and use of at least one primer.
6. Method according to any one of claim 1-5, wherein the step of detecting comprises a polymerase chain reaction and use of at least one primer and/or probe.
7. Method according to claims 5 or 6, wherein each primer comprises a sequence of at least 10 consecutive nucleotides selected from one of the sequences of a group consisting of SEQ ID NO. 24-25, 28-29, 32-33, 36-37, 40-41 , 44-45, 48-49, 52-53, 56-57 and 60-61.
8. Method according to any one of claims 5-7, wherein primers are used as primer pairs, selected from a group consisting of the following primer pairs:
primers according to SEQ ID NO. 24 and 25,
primers according to SEQ ID NO. 28 and 29,
primers according to SEQ ID NO. 32 and 33,
primers according to SEQ ID NO. 36 and 37,
primers according to SEQ ID NO. 40 and 41 ,
primers according to SEQ ID NO. 44 and 45,
primers according to SEQ ID NO. 48 and 49,
primers according to SEQ ID NO. 52 and 53,
primers according to SEQ ID NO. 56 and 57, and
primers according to SEQ ID NO. 60 and 61.
9. Method according to any one of the preceding claims 6-8, wherein the step of detecting comprises use of probes, wherein binding of a probe comprising a sequence of at least 10 consecutive nucleotides from
SEQ ID NO. 26, confirms the virus to have SNP S4-T320C
SEQ ID NO. 30, confirms the virus to have SNP S4-G754A
SEQ ID NO. 34, confirms the virus to have SNP M2-G551C
SEQ ID NO. 38, confirms the virus to have SNP M2-T580A
SEQ ID NO. 42, confirms the virus to have SNP M2-G784T
SEQ ID NO. 46, confirms the virus to have SNP M2-A1108G
SEQ ID NO. 50, confirms the virus to have SNP M3-A280T
SEQ ID NO. 54, confirms the virus to have SNP M3-C371T
SEQ ID NO. 58, confirms the virus to have SNP M3-A1351G
SEQ ID NO. 62 or 63, confirms the virus to have SNP M3-T1687C
10. Method according to any one of the preceding claims, wherein the presence of mutation M3-A280T and/or M3-A1351G in SEQ ID NO. 6 confirms the virus to cause high mortality.
11. Method according to any one of the preceding claims, wherein the presence of mutation M3-A280T, M3-C1064T, M3-A1351G, M3-T1421C and M3-T1687C in SEQ ID NO. 6 confirms the virus to cause high mortality.
12. Method according to any one of claims 1-9, wherein the presence of mutation M3-C371T in SEQ ID NO. 6 confirms the virus to cause moderate to low mortality, and morbidity.
13. Method according to any one of claims 1-9, wherein the presence of mutation M3-C371T, M3-C1064T and M3-T1421C in SEQ ID NO. 6 confirms the virus to cause moderate to low mortality, and morbidity.
14. Method according to any one of claims 1-9, wherein the presence of mutation S4-T320C in SEQ ID NO. 4 confirms the virus to cause high morbidity.
15. Method according to any one of claims 1-9, wherein the presence of mutation S4-G754A in SEQ ID NO. 4 confirms the virus to cause high to moderate mortality, and morbidity.
16. A primer or probe comprising a sequence of at least 10 consecutive nucleotides selected from the group comprising SEQ ID NO. 24-26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58 and 60-63.
17. Method for determining virulence of Piscine Orthoreovirus (PRV) in a biological sample from a fish, comprising the following steps,
a) isolating amino acid sequences of the sample,
b) sequencing the amino acid sequence, c) detecting whether any of the following amino acids are present in the amino acid sequences from the sample:
- A in position 107 or N in position 252 of SEQ I D NO. 1 ,
- T in position 184, I in position 194, S in position 262, A in position 320 or D in position 370 of SEQ ID NO. 2, or
- L in position 94, V in position 124, L in position 355, V in position 451 , T in position 474 or P in position 563 of SEQ ID NO. 3,
wherein the numbering of said positions are in accordance with the sequences 1 , 2 and 3, respectively,
wherein presence of at least one the amino acids confirms that the virus is virulent and will cause morbidity and/or mortality of the fish upon infection.
18. Method according to claim 17, wherein the presence of amino acid L in position 94, and/or V in position 451 in SEQ ID NO. 3 confirms the virus to cause high mortality.
19. Method according to claim 17, wherein the presence of L in position 94, L in position 355, V in position 451 , T in position 474 or P in position 563 of SEQ ID NO.
3 confirms the virus to cause high mortality.
20. Method according to claim 17, wherein the presence of V in position 124 of SEQ ID NO. 3 confirms the virus to cause moderate mortality, high morbidity.
21. Method according to claim 17, wherein the presence of V in position 124, L in position 355, or T in position 474 of SEQ ID NO. 3 confirms the virus to cause moderate mortality, high morbidity.
22. Method according to claim 17, wherein the presence of A in position 107 of SEQ ID NO. 1 confirms the virus to cause high morbidity.
23. Method according to claims 17, wherein the presence of N in position 252 of SEQ ID NO. 1 confirms the virus to cause moderate mortality, high morbidity.
EP20704957.8A 2019-01-30 2020-01-28 Piscine orthoreovirus virulence markers Pending EP3918095A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20190110A NO344967B1 (en) 2019-01-30 2019-01-30 Piscine Orthoreovirus Virulence Markers
PCT/NO2020/050017 WO2020159379A1 (en) 2019-01-30 2020-01-28 Piscine orthoreovirus virulence markers

Publications (1)

Publication Number Publication Date
EP3918095A1 true EP3918095A1 (en) 2021-12-08

Family

ID=69570802

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20704957.8A Pending EP3918095A1 (en) 2019-01-30 2020-01-28 Piscine orthoreovirus virulence markers

Country Status (5)

Country Link
EP (1) EP3918095A1 (en)
CA (1) CA3126580A1 (en)
CL (1) CL2021001992A1 (en)
NO (1) NO344967B1 (en)
WO (1) WO2020159379A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO346211B1 (en) * 2020-07-14 2022-04-19 Patogen As Piscine Orthoreovirus Virulence Markers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2482825B1 (en) 2009-10-02 2016-11-23 The Trustees of Columbia University in the City of New York Piscine reovirus diagnostic compositions
NO346439B1 (en) * 2014-06-03 2022-08-15 Veterinærinstituttet New reovirus infecting rainbow trout
WO2016075277A1 (en) * 2014-11-14 2016-05-19 Patogen Analyse As Novel fish virus and method for detection
GB201701480D0 (en) * 2017-01-30 2017-03-15 Aquagen As Disease resistance
WO2019110664A1 (en) * 2017-12-06 2019-06-13 Intervet International B.V. Use of a non-structural protein from prv to protect against heart and skeletal muscle inflammation

Also Published As

Publication number Publication date
CL2021001992A1 (en) 2022-01-28
WO2020159379A1 (en) 2020-08-06
WO2020159379A8 (en) 2020-10-08
NO344967B1 (en) 2020-08-03
CA3126580A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
Løvoll et al. Quantification of piscine reovirus (PRV) at different stages of Atlantic salmon Salmo salar production
Weber et al. Characterization of dog serum virome from Northeastern Brazil
Sutherland et al. Sex chromosome evolution, heterochiasmy, and physiological QTL in the salmonid brook charr Salvelinus fontinalis
Hamid et al. Molecular investigation of dengue virus serotype 2 circulation in Kassala state, Sudan
Kaján et al. Partial sequence of the DNA-dependent DNA polymerase gene of fowl adenoviruses: a reference panel for a general diagnostic PCR in poultry
Chingandu et al. Molecular characterization of previously elusive badnaviruses associated with symptomatic cacao in the New World
Biđin et al. Identification and phylogenetic diversity of parvovirus circulating in commercial chicken and turkey flocks in Croatia
Dalton et al. Conventional and real time RT-PCR assays for the detection and differentiation of variant rabbit hemorrhagic disease virus (RHDVb) and its recombinants
Kuehn et al. Identification of a piscine reovirus-related pathogen in proliferative darkening syndrome (PDS) infected brown trout (Salmo trutta fario) using a next-generation technology detection pipeline
Weber et al. Virome of crab-eating (Cerdocyon thous) and pampas foxes (Lycalopex gymnocercus) from southern Brazil and Uruguay
Tzen et al. Sequence polymorphism in the coding region of mitochondrial genome encompassing position 8389–8865
Grandjean et al. A new bunya-like virus associated with mass mortality of white-clawed crayfish in the wild
EP3199643B1 (en) Method of identification of european freshwater fish and hybrides in biological materials by s7icaps method
Asif et al. Characterisation of the whole genome sequence of an avian hepatitis E virus directly from clinical specimens reveals possible recombination events between European and USA strains
EP3918095A1 (en) Piscine orthoreovirus virulence markers
Isidan et al. Molecular analysis of goose parvovirus field strains from a Derzsy’s disease outbreak reveals local European-associated variants
Ndiana et al. Detection and genetic characterization of canine adenoviruses, circoviruses, and novel cycloviruses from wild carnivores in Italy
Gallagher et al. Genome-wide target enriched viral sequencing reveals extensive ‘hidden’salmonid alphavirus diversity in farmed and wild fish populations
WO2018138527A1 (en) Hsmi disease resistance in salmonids
Bennett et al. Butcherbird polyomavirus isolated from a grey butcherbird (Cracticus torquatus) in Queensland, Australia
Vigil et al. Comparison of de novo assembly using long-read shotgun metagenomic sequencing of viruses in fecal and serum samples from marine mammals
Tomaszewski et al. Tissue distribution of psittacid herpesviruses in latently infected parrots, repeated sampling of latently infected parrots and prevalence of latency in parrots submitted for necropsy
DK178926B1 (en) Predicting disease resistance
KR101617142B1 (en) Nucleic acid test based avian influenza virus detection kit with improved detection accuracy
Jaroenram et al. One base pair deletion and high rate of evolution: Keys to viral accommodation of Australian Penaeus stylirostris densovirus

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)